Rani Therapeutics' Oral Biologics Vision Faces Early-Stage Risks

Rani Therapeutics Holdings, Inc. is a biotechnology firm aiming to revolutionize how biologic drugs are delivered through their RaniPill robotic capsule, which injects liquid medication directly into the intestinal wall. While their oral biologics vision has the potential to benefit patients, it still carries early-stage risks, including regulatory hurdles, competition, and technological challenges. Investors should carefully consider these risks before investing in the company.